Is a biotech bubble inflating in China? Do the feds coddle CEOs? And why don’t clinical trials look like America?
We discuss all that and more on this week’s episode of “The Readout LOUD,” STAT’s biotech podcast. Tune in for an interview with Michael Chan, the man tasked with convincing biotech companies to go public on the Hong Kong Stock Exchange, about how that experiment is going. Then we dig into saga surrounding Clovis Oncology, which went from a Wall Street darling to a cautionary tale before paying an arguably minuscule price for its alleged misdeeds. And then ProPublica reporter Caroline Chen joins us to discuss why African-Americans are vastly underrepresented in cancer clinical trials. Finally, there’s a lightning round, exploring an odd move by PhRMA, a second act for an accused insider trader, and the drug industry’s latest star turn in Hollywood.
For more on what we cover, here’s the latest on Clovis; here’s the story on clinical trial diversity; and here’s the news on PhRMA’s interest in housing policy.
We’ll be back next Thursday evening — and every Thursday evening — so be sure to sign up on iTunes, Stitcher, Google Play, or wherever you get your podcasts.
And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].
Interested in sponsoring a future episode of “The Readout LOUD”? Email us at [email protected].
